Palau Pharma, S.a.

Helsinn Therapeutics (u.s.), Inc.

Axcentua Pharmaceuticals Ab

Takeda Pharmaceutical Company Limited

Sanofi-Aventis

Helsinn Healthcare Sa

Bial-Portela Ca & S.a.

Stiefel Laboratories, Inc.

Noramco Gmbh

Harbor Therapeutics, Inc.

Neurmedix, Inc.

Axcentua Pharmaceutucals Ab

Keith Lorimer

Benjamin Joseph Littler

Seemon H Pines

Bernhard J Paul

Steven K White

Brenton Skylar Wolfe

Anders Berkenstam

Javier Bartroli Orpi

Stefan Rehnmark

Michael-Robin Witt

Stephen Watt

Antonio Cánovas Paredes

Elies Molins Grau

Anna Roig Serra

Kevin Meyer

David Alexander Learmonth

Mark Andres

Kevin Wayne Meyer

Tibor Eszenyi

Alicia Tee Fuay Ng

Erin E Jansen

Alicia T Ng

Álmosné Kovách

Erin Olson

Paul Bernhard

Benjamin Litter

Crystalline forms of anamorelin which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.

Crystal forms of anamorelin

The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to methods of treating cancer comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the compounds of the disclosure, of a crystalline form of genistein, or of a genistein salt.

Crystalline forms of genistein

The invention provides and describes solid state 17&#x3b1;-ethynyl-5&#x3b1;-androstane-3&#x3b1;,17&#x3b2;-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17&#x3b1;-ethynyl-5&#x3b1;-androstane-3&#x3b1;,17&#x3b2;-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17&#x3b1;-ethynyl-5&#x3b1;-androstane-3&#x3b1;,17&#x3b2;-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17&#x3b1;-ethynyl-5&#x3b1;-androstane-3&#x3b1;,17&#x3b2;-diol and uses of such formulations in treating the described conditions.

Methods of preparing pharmaceutical solid state forms

This invention relates to novel polymorphs of (HO)NO(CH)&#x2014;(CNO)&#x2014;(CN)(CH)ClO, to processes for their preparation, and to pharmaceutical compositions containing said novel polymorphs as active pharmaceutical ingredient.

Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4] oxadiazol-5-yl]-3-nitrobenzene-1,2-diol

Pharmaceutical solid state forms

Crystalline polymorphs of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.

Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide

Methods of making polymorphs of the benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile.

Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile

The present subject matter relates to novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one represented by Formula II: , pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV V, and VI of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one.

Crystalline antifungal compounds

Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2 -hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV, V, and VI of (1R,2R)-7-chloro-3-[2 -(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin -4(3H)-one, represented by formula II: 

The invention relates to methyl(+)-(S)-&#x3b1;-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate naphthalene-1,5-disulfonate or a polymorphic form and/or a hydrate and/or a solvate thereof, to pharmaceutical compositions containing the same, and to the method of use thereof for inhibiting platelet aggregation.

Clopidogrel salt and polymorphic forms thereof

Hydromorphone hydrochloride forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydromorphone hydrochloride.

Hydromorphone polymorphs

Growing community of inventors

West Lafayette, IN, United States of America

Keith Lorimer